Due to the slowing of the gastrointestinal tract caused by GLP-1 receptor agonists, some patients may experience stomach pains or constipation
Food and Drug Administration) In the U.S., FDA warning letters issued in 2024 and 2025 targeted multiple online peptide sellers offering products such as semaglutide, tirzepatide, retatrutide, cagrilintide, mazdutide, and others
Amantadine in the prevention of clinical symptoms caused by SARS-CoV-2
Given the multifactorial nature of glaucoma-associated ocular surface disease (G-OSD)which involves chronic inflammation, oxidative stress, and tear film instabilitydeveloping novel therapies that target these intersecting pathways is of considerable clinical relevance
If you'd like to keep these notes alongside your other GLP-1 tracking, The GLP-1 Journal lets you log daily symptoms privately
Sources van den Hout, W